Literature DB >> 20802350

Prognostic factors for survival after surgical palliation of malignant pleural effusion.

John E Pilling1, Michael E Dusmet, George Ladas, Peter Goldstraw.   

Abstract

INTRODUCTION: To investigate prognostic factors for patient survival after surgical palliation of malignant pleural effusion (MPE).
METHOD: We reviewed 278 consecutive nonoverseas patients (108 men, median age: 60 years [range 26-89]) undergoing 310 surgical procedures for palliation of MPE over a 72-month period. There were 195 thoracoscopic talc pleurodesis, 39 pleuroperitoneal shunts, 38 pleurodesis by an intercostal drain, 29 pleural biopsies alone, and nine long-term drains. Referring physicians provided survival data. The significance of prognostic factors was examined with the log-rank test (Kaplan-Meier), those significant entered a Cox logistic multivariate regression analysis.
RESULTS: Follow-up was complete until death (following 264 procedures) and for a median 648 days (range 173-2135) for surviving patients. Overall median postoperative survival was 211 days (95% confidence interval: 169-253). Survival was not significantly different for tumor type or method of palliation. In univarate analysis, preoperative leucocytosis, hypoxemia, raised alanine transaminase, body mass index below 18 and hypoalbuminemia were associated with a significantly reduced postoperative survival. In multivariate analysis, leucocytosis (p < 0.0001), hypoxemia (p = 0.014), and hypoalbuminemia (p < 0.0001) maintained significance.
CONCLUSIONS: The survival reported demonstrates the necessity of an active approach to palliation of MPE. The identification of prognostic factors will assist the choice of palliative technique. In addition, an appreciation of the influence of selection on survival after surgical palliation of malignant pleural mesothelioma, especially that of unforeseen prognostic factors, is useful when evaluating the results of aggressive treatment such as chemoradiotherapy and radical surgery for these diseases.

Entities:  

Mesh:

Year:  2010        PMID: 20802350     DOI: 10.1097/JTO.0b013e3181e95cb8

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  18 in total

1.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  Mortality among patients with pleural effusion undergoing thoracentesis.

Authors:  Erin M DeBiasi; Margaret A Pisani; Terrence E Murphy; Katy Araujo; Anna Kookoolis; A Christine Argento; Jonathan Puchalski
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

3.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Authors:  Charu Aggarwal; Andrew R Haas; Susan Metzger; Laura K Aguilar; Estuardo Aguilar-Cordova; Andrea G Manzanera; Gregoria Gómez-Hernández; Sharyn I Katz; Evan W Alley; Tracey L Evans; Joshua M Bauml; Roger B Cohen; Corey J Langer; Steven M Albelda; Daniel H Sterman
Journal:  Mol Ther       Date:  2018-02-21       Impact factor: 11.454

Review 7.  Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions.

Authors:  Marc Fortin; Alain Tremblay
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

8.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

9.  Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial.

Authors:  Athanasios Kleontas; Antonia Sioga; Niki Pandria; Nikolaos Barbetakis; Achilleas Lazopoulos; Ioannis Katsikas; Christos Asteriou; Dimitrios Paliouras; Efstathios Kamperis; Dimitrios Ikonomou; Theodora Papamitsou; Dimitrios Filippou; Chariklia Destouni; Louiza Ikonomou; Konstantinos Zarogoulidis; Kostas Papagiannopoulos
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

10.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.

Authors:  Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell
Journal:  Thorax       Date:  2014-08-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.